Twenty-five years ago, Georges Köhler and César Milstein invented a means of
cloning individual antibodies, thus opening up the way for tremendous advances in the
fields of cell biology and clinical diagnostics (1). However, in spite of their early
promise, monoclonal antibodies (MAbs) were largely unsuccessful as therapeutic
reagents resulting from insufficient activation of human effector functions and
immune reactions against proteins of murine origin.
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis...
Most traditional pharmaceutical drugs are relatively small molecules that bind to particular molecular targets and either activate or deactivate biological processes. Small molecules are typically manufactured through traditional organic synthesis, and many can be taken orally. In contrast, Biopharmaceuticals are large biological molecules such as proteins that are developed to address targets that cannot easily be addressed by small molecules.